Theolytics
PrivateLast Round
Grant
Mar 4, 2026
Total Funding Raised
$21.11M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Theolytics is a biotechnology company that develops oncolytic immunotherapies using a proprietary phenotypic screening platform to target and destroy cancer cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Theolytics Comparables
Compare Theolytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TILT Biotherapeutics | 90% | |
| ORCA Therapeutics | 84% | |
| Humane Genomics | 83% | |
Theolytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2026 | ||||
| Grant | Sep 2, 2024 | ||||
| VC Round | Apr 17, 2024 | ||||
| Grant | Jun 1, 2022 | ||||
| Series A Extension | Jul 8, 2021 | ||||
Series A | Jan 7, 2021 |
Key People
Founding team and executive leadership
Theolytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Epidarex Capital | VC Round, Series A Extension, Series A |
| Oxford Science Enterprises | VC Round, Series A, Seed |
| Taiho Ventures | VC Round, Series A Extension, Series A |
| M Ventures | VC Round, Series A Extension |
| UKRI Innovate UK | Grant |
| Horizon Europe | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
$9.3M raised in a grant round.
- Oct 1, 2025
Matilde Saggese, MD, appointed as new CMO.
Theolytics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Theolytics's valuation, stock price, and market status.